Results 111 to 120 of about 16,895 (259)

Establishment of a mouse model for ischaemic heart failure induced by coronary microembolization via left ventricular oil injection

open access: yesExperimental Physiology, EarlyView.
Abstract Over the past three decades, there has been a steady increase in clinical attention to ischaemic heart failure caused by coronary microembolization. Nonetheless, a suitable mouse model for studying this condition remains limited. In the present study, we developed a mouse model of coronary microembolization‐induced ischaemic heart failure by ...
Lang Pei   +10 more
wiley   +1 more source

Copper Transporters? Glutathione Reactivity of Products of Cu–Aβ Digestion by Neprilysin [PDF]

open access: hybrid, 2020
Ewelina Stefaniak   +4 more
openalex   +1 more source

Neprilysin

open access: yesJACC: Heart Failure, 2015
Marie-France Seronde, Alexandre Mebazaa
openaire   +1 more source

Ablation of Ventricular Tachycardia Using the QDOT MICRO Ablation Catheter (VT‐MICRO Study)

open access: yesJournal of Arrhythmia, Volume 42, Issue 1, February 2026.
Catheter ablation is useful to treat patients with ventricular tachycardia. QDOT Micro catheter is a next generation catheter designed to provide more efficient lesion creation with an accurate myocardial substrate analysis. Microelectrode mapping allows detection of higher voltage electrograms compared to standard bipolar mapping and Pentaray mapping.
Antonio Di Monaco   +6 more
wiley   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton   +9 more
wiley   +1 more source

Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date

open access: yesDrug Design, Development and Therapy, 2016
José Fernando Vilela-Martin Internal Medicine Department, São José do Rio Preto State Medical School (FAMERP), São José do Rio Preto, Brazil Abstract: Heart failure is a global problem with elevated prevalence, and it
Vilela-Martin JF
doaj  

Home - About - Disclaimer - Privacy